+

WO1993014122A1 - Variant inhibiteur de la protease humaine de type kunitz - Google Patents

Variant inhibiteur de la protease humaine de type kunitz Download PDF

Info

Publication number
WO1993014122A1
WO1993014122A1 PCT/DK1993/000005 DK9300005W WO9314122A1 WO 1993014122 A1 WO1993014122 A1 WO 1993014122A1 DK 9300005 W DK9300005 W DK 9300005W WO 9314122 A1 WO9314122 A1 WO 9314122A1
Authority
WO
WIPO (PCT)
Prior art keywords
phe
amino acid
arg
variant according
lys
Prior art date
Application number
PCT/DK1993/000005
Other languages
English (en)
Inventor
Fanny Norris
Kjeld Norris
Søren Erik BJØRN
Lars Christian Petersen
Ole Hvilsted Olsen
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Priority to JP5511993A priority Critical patent/JPH07504891A/ja
Priority to AU33460/93A priority patent/AU675926B2/en
Priority to EP93902106A priority patent/EP0621872A1/fr
Publication of WO1993014122A1 publication Critical patent/WO1993014122A1/fr
Priority to NO942549A priority patent/NO942549L/no
Priority to FI943234A priority patent/FI943234A0/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to a variant of a human Kunitz- type protease inhibitor domain, DNA encoding the variant, a method of producing the variant and a pharmaceutical composition containing the variant.
  • Polymorphonuclear leukocytes (neutrophils or PMNs) and mononuclear phagocytes (monocytes) play an important part in tissue injury, infection, acute and chronic inflammation and wound healing.
  • the cells migrate from the blood to the site of inflammation and, following appropriate stimulation, they release oxidant compounds (O 2 ⁇ , O 2 -, H 2 O 2 and HOCl) as well as granules containing a variety of proteolytic enzymes.
  • the secretory granules contain, i.a., alkaline phosphatase, metalloproteinases such as gelatinase and collagenase and serine proteases such as neutrophil elastase, cathepsin G and proteinase 3.
  • Latent metalloproteinases are released together with tissue inhibitor of metalloproteinase (TIMP).
  • TIMP tissue inhibitor of metalloproteinase
  • the serine proteases neutrophil elastase, cathepsin G and proteinase-3 are packed as active enzymes complexed with glucosaminoglycans. These complexes are inactive but dissociate on secretion to release the active enzymes.
  • To neutralise the protease activity large amounts of the inhibitors ⁇ 1 -proteinase inhibitor ( ⁇ 1 -PI) and ⁇ 1 -chymotrypsin inhibitor ( ⁇ 1 -Chl) are found in plasma. However, the PMNs are able to inactivate the inhibitors locally.
  • ⁇ 1 -PI which is the most important inhibitor of neutrophil elastase is sensitive to oxidation at the reactive centre (Met- 358) by oxygen metabolites produced by triggered PMNs. This reduces the affinity of ⁇ 1 -PI for neutrophil elastase by approximately 2000 times.
  • the elastase After local neutralisation of ⁇ 1 -PI, the elastase is able to degrade a number of inhibitors of other proteolytic enzymes. Elastase cleaves ⁇ 1 -ChI and thereby promotes cathepsin G activity. It also cleaves TIMP, resulting in tissue degradation by metalloproteinases. Furthermore, elastase cleaves antithrombin III and heparin cofactor II, and tissue factor pathway inhibitor (TFPI) which probably promotes clot formation. On the other hand, the ability of neutrophil elastase to degrade coagulation factors is assumed to have the opposite effect so that the total effect of elastase is unclear.
  • the effect of neutrophil elastase on fibrinolysis is less ambiguous. Fibrinolytic activity increases when the elastase cleaves the plasminogen activator inhibitor and the ⁇ 2 plasmin inhibitor. Besides, both of these inhibitors are oxidated and inactivated by O 2 metabolites.
  • PMNs contain large quantities of serine proteases, and about 200 mg of each of the leukocyte proteases are released daily to deal with invasive agents in the body. Acute inflammation leads to a many-fold increase in the amount of enzyme released. Under normal conditions, proteolysis is kept at an acceptably low level by large amounts of the inhibitors ⁇ 1 -PI, ⁇ 1 -ChI and ⁇ 2 macroglobulin. There is some indication, however, that a number of chronic diseases is caused by pathological proteolysis due to overstimulation of the PMNs, for instance caused by autoimmune response, chronic infection, tobacco smoke or other irritants, etc.
  • Aprotinin (bovine pancreatic trypsin inhibitor) is known to inhibit various serine proteases, including trypsin, chymotrypsin, plasmin and kallikrein, and is used therapeutically in the treatment of acute pancreatitis, various states of shock syndrome, hyperfibrinolytic haemorrhage and myocardial infarction (cf., for instance, J.E. Trapnell et al, Brit. J. Surg. 61, 1974, p. 177; J. McMichan et al., Circulatory shock 9, 1982, p. 107; L.M. Auer et al., Acta Neurochir. 49, 1979, p. 207; G. Sher, Am.
  • aprotininin analogues e.g. aprotinin(1-58, Vall5) exhibits a relatively high selectivity for granulocyte elastase and an inhibitory effect on collagenase
  • aprotinin (1-58, Ala15) has a weak effect on elastase
  • aprotinin (3-58, Arg15, Ala17, Ser42) exhibits an excellent plasma kallikrein inhibitory effect (cf. WO 89/10374).
  • aprotinin when administered in vivo, aprotinin has been found to have a nephrotoxic effect in rats, rabbits and dogs after repeated injections of relatively high doses of aprotinin
  • aprotinin is a bovine protein which may therefore contain one or more epitopes which may give rise to an undesirable immune response on administration of aprotinin to humans.
  • the present invention relates to a variant of human Kunitz-type protease inhibitor domain I of tissue factor pathway inhibitor (TFPI), the variant comprising the following amino acid sequence
  • X 11 X 12 X 13 Gln Asn Arg Phe X 14 Ser Leu Glu Glu Cys X 15 X 16 Met Cys Thr Arg X 17 (SEQ ID No. 1) wherein X 1 represents H or 1-7 naturally occurring amino acid residues except Cys, X 2 -X 16 each independently represents a naturally occurring amino acid residue except Cys, and X 17 represents OH or 1-5 naturally occurring amino acid residues except Cys, with the proviso that at least one of the amino acid residues X 1 -X 17 is different from the corresponding amino acid residue of the native sequence.
  • the term "naturally occurring amino acid residue” is intended to indicate any one of the 20 commonly occurring amino acids, i.e. Ala, Val, Leu, lle Pro, Phe, Trp, Met, Gly, Ser, Thr, Cys, Tyr, Asn, Gln, Asp, Glu, Lys, Arg and His.
  • TFPI also known as extrinsic pathway inhibitor (EPI) or lipoprotein associated coagulation inhibitor (LACI)
  • EPI extrinsic pathway inhibitor
  • LACI lipoprotein associated coagulation inhibitor
  • Kunitz-type domain I of TFPI has been shown to bind TF/FVIIa, while Kunitz-type domain II has been shown to bind to FXa (Girard et al., Nature 338, 1989, pp. 518-520).
  • TFPI Kunitz-type domain I By substituting one or more amino acids in one or more of the positions indicated above, it may be possible to change the inhibitor profile of TFPI Kunitz-type domain I so that it preferentially inhibits neutrophil elastase, cathepsin G and/or proteinase-3. Furthermore, it may be possible to construct variants which specifically inhibit enzymes involved in coagulation or fibrinolysis (e.g. plasmin or plasma kallikrein) or the complement cascade.
  • enzymes involved in coagulation or fibrinolysis e.g. plasmin or plasma kallikrein
  • TFPI Kunitz-type domain I has a negative net charge as opposed to aprotinin which, as indicated above, has a strongly positive net charge. It is therefore possible to construct variants of the invention with a lower positive net charge than aprotinin, thereby reducing the risk of kidney damage on administration of large doses of the variants. Another advantage is that, contrary to aprotinin, it is a human protein (fragment) so that undesired immunological reactions on administration to humans are significantly reduced.
  • X 1 is Ser-Phe or Met-His-Ser-Phe
  • X 2 is an amino acid residue selected from the group consisting of Ala, Arg, Thr, Asp, Pro, Glu, Lys, Gln, Ser, lle and Val, in particular wherein X 2 is Thr or Asp
  • X 3 is an amino acid residue selected from the group consisting of Pro, Thr, Leu, Arg, Val and lle, in particular wherein X 3 is Pro or lle
  • X 4 is an amino acid residue selected from the group consisting of Lys, Arg, Val, Thr, lle, Leu, Phe, Gly, Ser, Met, Trp, Tyr, Gln, Asn and Ala, in particular wherein X 4 is Lys, Val, Leu, lle, Thr, Met, Gln or Arg; or wherein X 5 is an amino acid residue selected from the group consisting of Lys, Arg, Val, Thr, Met, Gln
  • Variants of TFPI Kunitz-type domain I of the invention should preferably not contain a Met residue in the protease binding region (i.e. the amino acid residues represented by X 3 -X 14 ).
  • a Met residue in any one of these positions would make the inhibitor sensitive to oxidative inactivation by oxygen metabolites produced by PMNs, and conversely, lack of a Met residue in these positions should render the inhibitor more stable in the presence of such oxygen metabolites.
  • a currently preferred variant of the invention is one in which one or more of the amino acid residues located at the protease- binding site of the Kunitz domain (i.e. one or more of X 3 -X 14 corresponding to positions 13, 15, 16, 17, 18, 19, 20, 34, 39, 40, 41 and 46 of aprotinin) are substituted to the amino acids present in the same positions of native aprotinin.
  • This variant comprises the following amino acid sequence
  • the invention in another aspect, relates to a DNA construct encoding a human Kunitz-type inhibitor domain variant according to the invention.
  • the DNA construct of the invention may be prepared synthetically by established standard methods, e.g. the phosphoamidite method described by S.L. Beaucage and M.H. Caruthers, Tetrahedron Letters 22, 1981, pp. 1859-1869, or the method described by Matthes et al., EMBO Journal 3, 1984, pp. 801-805.
  • oligonucleotides are synthesized, e.g. in an automatic DNA synthesizer, purified, annealed, ligated and cloned in suitable vectors.
  • genomic or cDNA coding for TFPI Kunitz-type domain I e.g. obtained by screening a genomic or cDNA library for DNA coding for TFPI using synthetic oligonucleotide probes and isolating the DNA sequence coding for domain I therefrom).
  • the DNA sequence is modified at one or more sites corresponding to the site(s) at which it is desired to introduce amino acid substitutions, e.g. by site-directed mutagenesis using synthetic oligonucleotides encoding the desired amino acid sequence for homologous recombination in accordance with well-known procedures.
  • the invention relates to a recombinant expression vector which comprises a DNA construct of the invention.
  • the recombinant expression vector may be any vector which may conveniently be subjected to recombinant DNA procedures, and the choice of vector will often depend on the host cell into which it is to be introduced.
  • the vector may be an autonomously replicating vector, i.e. a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g. a plasmid.
  • the vector may be one which, when introduced into a host cell, is integrated into the host cell genome and replicated together with the chromosome(s) into which it has been integrated.
  • the DNA sequence encoding the TFPI Kunitz-type domain I variant of the invention should be operably connected to a suitable promoter sequence.
  • the promoter may be any DNA sequence which shows transcriptional activity in the host cell of choice and may be derived from genes encoding proteins either homologous or heterologous to the host cell.
  • suitable promoters for directing the transcription of the DNA encoding the TFPI Kunitz-type domain I variant of the invention in mammalian cells are the SV 40 promoter (Subramani et al., Mol. Cell Biol. 1, 1981, pp. 854-864), the MT-1 (metallothionein gene) promoter (Palmiter et al., Science 222, 1983, pp.
  • Suitable promoters for use in yeast host cells include promoters from yeast glycolytic genes (Hitzeman et al., J. Biol. Chem. 255, 1980, pp. 12073- 12080; Alber and Kawasaki, J. Mol. Appl. Gen. 1, 1982, pp. 419- 434) or alcohol dehydrogenase genes (Young et al., in Genetic Engineering of Microorganisms for Chemicals (Hollaender et al, eds.), Plenum Press, New York, 1982), or the TPI1 (US 4, 599, 311) or ADH2-4C (Russell et al., Nature 304. 1983, pp.
  • promoters for use in filamentous fungus host cells are, for instance, the ADH3 promoter (McKnight et al., The EMBO J. 4, 1985, pp. 2093-2099) or the tpiA promoter.
  • the DNA sequence encoding the TFPI Kunitz-type domain I variant of the invention may also be operably connected to a suitable terminator, such as the human growth hormone terminator (Palmiter et al., op. cit.) or (for fungal hosts) the TPI1 (Alber and Kawasaki, op. cit.) or ADH3 (McKnight et al., op. cit.) promoters.
  • the vector may further comprise elements such as polyadenylation signals (e.g. from SV 40 or the adenovirus 5 Elb region), transcriptional enhancer sequences (e.g. the SV 40 enhancer) and translational enhancer sequences (e.g. the ones encoding adenovirus VA RNAs).
  • the recombinant expression vector of the invention may further comprise a DNA sequence enabling the vector to replicate in the host cell in question.
  • a sequence when the host cell is a mammalian cell
  • the SV 40 origin of replication or (when the host cell is a yeast cell) the yeast plasmid 2 ⁇ replication genes REP 1-3 and origin of replication.
  • the vector may also comprise a selectable marker, e.g. a gene the product of which complements a defect in the host cell, such as the gene coding for dihydrofolate reductase (DHFR) or one which confers resistance to a drug, e.g. neomycin, hygromycin or methotrexate, or the Schizosaccharomyces pombe TPI gene (described by P.R. Russell, Gene 40, 1985, pp. 125-130.
  • DHFR dihydrofolate reductase
  • the host cell into which the expression vector of the invention is introduced may be any cell which is capable of producing the TFPI Kunitz-type domain I variant of the invention and is preferably a eukaryotic cell, such as a mammalian, yeast or fungal cell.
  • the yeast organism used as the host cell according to the invention may be any yeast organism which, on cultivation, produces large quantities of the TFPI Kunitz-type domain I variant of the invention.
  • suitable yeast organisms are strains of the yeast species Saccharomyces cerevisiae, Saccharomyces kluyveri, Schizosaccharomvces pombe or Saccharomyces uvarum.
  • the transformation of yeast cells may for instance be effected by protoplast formation followed by transformation in a manner known per se.
  • suitable mammalian cell lines are the COS (ATCC CRL 1650), BHK (ATCC CRL 1632, ATCC CCL 10) or CHO (ATCC CCL 61) cell lines.
  • Methods of transfecting mammalian cells and expressing DNA sequences introduced in the cells are described in e.g. Kaufman and Sharp, J. Mol. Biol. 159, 1982, pp. 601-621; Southern and Berg, J. Mol. APPI. Genet. 1, 1982, pp. 327-341; Loyter et al., Proc. Natl. Acad. Sci. USA 79, 1982, pp. 422-426; Wigler et al., Cell 14, 1978, p.
  • fungal cells may be used as host cells of the invention.
  • suitable fungal cells are cells of filamentous fungi, e.g. Aspergillus spp. or Neurospora spp., in particular strains of Aspergillus oryzae or Aspergillus niger.
  • Aspergillus spp. for the expression of proteins is described in, e.g., EP 238 023.
  • the present invention further relates to a method of producing a TFPI Kunitz-type domain I variant according to the invention, the method comprising culturing a cell as described above under conditions conducive to the expression of the variant and recovering the resulting variant from the culture.
  • the medium used to cultivate the cells may be any conventional medium suitable for growing mammalian cells or fungal (including yeast) cells, depending on the choice of host cell.
  • the variant will be secreted by the host cells to the growth medium and may be recovered therefrom by conventional procedures including separating the cells from the medium by centrifugation or filtration, precipitating the proteinaceous components of the supernatant or filtrate by means of a salt, e.g. ammonium sulfate, purification by a variety of chromatographic procedures, e.g. ion exchange chromatography or affinity chromatography, or the like.
  • the present invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a TFPI Kunitz-type domain I variant of the invention together with a pharmaceutically acceptable carrier or excipient.
  • the variant may be formulated by any of the established methods of formulating pharmaceutical compositions, e.g. as described in Remington's Pharmaceutical Sciences, 1985.
  • the composition may typically be in a form suited for systemic injection or infusion and may, as such, be formulated with sterile water or an isotonic saline or glucose solution. It has surprisingly been found that the TFPI Kunitz-type domain I is in itself capable of inhibiting Cathepsin G.
  • the invention therefore also relates to a pharmaceutical composition for the inhibition of Cathepsin G, the composition comprising human Kunitz-type protease inhibitor domain I of TFPI or a variant thereof as described above and a pharmaceutically acceptable carrier or excipient.
  • the TFPI Kunitz-type domain I variant of the invention is therefore contemplated to be advantageous to use for the therapeutic applications suggested for native aprotinin or aprotinin analogues with other inhibitor profiles, in particular those which necessitate the use of large aprotinin doses.
  • Therapeutic applications for which the use of the variant of the invention is indicated as a result of its ability to inhibit human serine proteases, e.g.
  • trypsin, plasmin, kallikrein, elastase, cathepsin G and proteinase-3 include (but are not limited to) acute pancreatitis, inflammation, thrombocytopenia, preservation of platelet function, organ preservation, wound healing, shock (including shock lung) and conditions involving hyperfibrinolytic haemorrhage, emphysema, rheumatoid arthritis, adult respiratory distress syndrome, chronic inflammatory bowel disease and psoriasis, in other words diseases presumed to be caused by pathological proteolysis by elastase, cathepsin G and proteinase-3 released from triggered PMNs.
  • the present invention relates to the use of TFPI Kunitz-type inhibitor domain I or a variant thereof as described above for the preparation of a medicament for the prevention or therapy of diseases or conditions associated with pathological proteolysis by proteases released from overstimulated PMNs. As indicated above, it may be an advantage of administer heparin concurrently with the TFPI Kunitz-type inhibitor domain I or variant.
  • TFPI Kunitz- type domain II or a variant thereof as specified above may be used to isolate useful natural substances, e.g. proteases or receptors from human material, which bind directly or indirectly to TFPI Kunitz-type domain II, for instance by screening assays or by affinity chromatography.
  • useful natural substances e.g. proteases or receptors from human material
  • affinity chromatography e.g. affinity chromatography
  • Amino acid analysis was carried out after hydrolysis in 6M HCl at 110°C in vacuum-sealed tubes for 24 hours. Analysis was performed on a Beckman 121MB automatic amino acid analyzer modified for microbore operation.
  • N-terminal amino acid sequence analysis was obtained by automated Edman degradation using an Applied Biosystems 470A gas-phase sequencer. Analysis by on-line reverse phase HPLC was performed for the detection and quantitation of the liberated pTH amino acids from each sequencer cycle.
  • Molecular weight determination was obtained on a BIO-ION 20 plasma desorption mass spectrometer (PDMS) equipped with a flight tube of approximately 15 cm and operated in positive mode. Aliquots of 5 ⁇ l were analyzed at an accelerating voltage set to 15 kV and ions were collected for 5 million fission events. The accuracy on assigned molecular ions is approximately 0.1% for well defined peaks, otherwise somewhat less.
  • PDMS BIO-ION 20 plasma desorption mass spectrometer
  • TFPI-1 tissue factor pathway inhibitor
  • yeast strain KFN-1651 cDNA encoding full length TFPI was isolated from the human liver derived cell line HepG2 (ATCC HB 8065) and inserted as a 0.9 kb BamHI-Xbal fragment into a mammalian expression vector, pKFN- 1168, as described (Pedersen, A.H., Nordfang, O., Norris, F., Wiberg, F.C., Christensen, P.M., Moeller, K. B., Meidahl- Pedersen, J., Beck, T.C., Norris, K., Hedner, U., and Kisiel, W.
  • TFPI-1 is encoded by nucleotides 152-325 as indicated.
  • TFPI-1 0.1 ⁇ g of the 0.9 kb BamHI-Xbal fragment from pKFN-1168 was used as a template in a PCR reaction containing 100 pmole each of the primers NOR-2524
  • NOR-2524 (GCTGAGAGATTGGAGAAGAGAATGCATTCATTTTGTGC) and NOR-2525 (TAATCCTTCTAGATTAATCTCTTGTACACAT).
  • the 17 3'-terminal bases of NOR-2524 are identical to bases 152 to 168 in the TFPI-1 gene in SEQ ID No. 3, and the 21 5'-terminal bases are identical to bases 215 to 235 in the synthetic leader gene (see SEQ ID No. 5) from pKFN-1000 described below.
  • Primer NOR-2525 is complementary to bases 311 to 325 in SEQ ID No. 3 and has a 5' extension containing a translation stop codon followed by an Xbal site.
  • the PCR reaction was performed in a 100 ⁇ l volume using a commercial kit (GeneAmp, Perkin Elmer Cetus) and the following cycle: 94° for 20 sec, 50° for 20 sec, and 72° for 30 sec. After 19 cycles a final cycle was performed in which the 72° step was maintained for 10 min.
  • the PCR product, a 211 bp fragment, was isolated by electrophoresis on a 2% agarose gel.
  • Signal-leader 0.1 ⁇ g of a 0.7 kb PvuII fragment from pKFN-1000 described below was used as a template in a PCR reaction containing 100 pmole each of the primers NOR-1478
  • NOR- 1478 is matching a sequence just upstream of the EcoRI site in SEQ ID No. 5.
  • Primer NOR-2523 is complementary to the 17 3'- terminal bases of the synthetic leader gene of pKFN-1000, see SEQ ID No. 5. The PCR reaction was performed as described above, resulting in a 257 bp fragment.
  • Plasmid pKFN-1000 is a derivative of plasmid pTZ19R (Mead, D.A., Szczesna-Skorupa, E. and Kemper, B., Prot. Engin. 1 (1986) 67- 74) containing DNA encoding a synthetic yeast signal-leader peptide.
  • Plasmid pKFN-1000 is described in WO 90/10075.
  • the DNA sequence of 235 bp downstream from the EcoRI site of pKFN-1000 and the encoded amino acid sequence of the synthetic yeast signal-leader is given in SEQ ID No. 5.
  • Signal-leader-TFPI-1 Approx. 0.1 ⁇ g of each of the two PCR- fragments described above were mixed. A PCR reaction was performed using 100 pmole each of primers NOR-1478 and NOR-2525 and the following cycle: 94° for 1 min, 50° for 2 min, and 72° for 3 min. After 16 cycles a final cycle was performed in which the 72° step was maintained for 10 min.
  • Plasmid pMT636 is described in WO 89/01968.
  • pMT636 is an E. coli - S. cerevisiae shuttle vector containing the Schizosaccharomyces pombe TPI gene (POT) (Russell, P.R., Gene 40 (1985) 125-130), the S. cerevisiae triosephosphate isomerase promoter and terminator, TPI p and TPI T (Alber, T., and Kawasaki, G., J.Mol.APPI.Gen. 1 (1982), 419-434).
  • POT Schizosaccharomyces pombe TPI gene
  • the ligation mixture was used to transform a competent E. coli strain (r-, m + ) selecting for ampicillin resistance. DNA sequencing showed that plasmids from the resulting colonies contained the correct DNA sequence for TFPI-1 correctly fused to the synthetic yeast signal-leader gene.
  • pKFN-1603 was selected for further use. The construction of plasmid pKFN-1603 is illustrated in fig. 1.
  • the expression cassette of plasmid pKFN-1603 contains the following sequence:
  • S. cerevisiae strain MT663 (E2-7B XE11-36 a/ ⁇ , ⁇ tpi/ ⁇ tpi, pep 4-3/pep 4-3) was grown on YPGaL (1% Bacto yeast extract, 2% Bacto peptone, 2% galactose, 1% lactate) to an O.D. at 600 nm of 0.6.
  • Transformant colonies were picked after 3 days at 30°C, reisolated and used to start liquid cultures.
  • One such transformant KFN-1651 was selected for further characterization.
  • Yeast strain KFN-1651 was grown on YPD medium (1% yeast extract, 2% peptone (from Difco Laboratories), and 3% glucose). A 1 liter culture of the strain was shaken at 30°C to an optical density at 650 nm of 24. After centrifugation the supernatant was isolated.
  • YPD medium 1% yeast extract, 2% peptone (from Difco Laboratories), and 3% glucose.
  • the yeast supernatant was adjusted to pH 3.0 with 5% acetic acid and phosphoric acid and applied a column of S-Sepharose Fast Flow (Pharmacia) and equilibrated with 50 mM formic acid, pH 3.7. After wash with equilibration buffer, the HKI-domain was eluted with 1 M sodium chloride. Desalting was obtained on a Sephadex G-25 column (Pharmacia) equilibrated and eluted with 0.1% ammonium hydrogen carbonate, pH 7.9. After concentraton by vacuum centifugation and adjustment of pH 3.0 further purification was performed on a Mono S column (Pharmacia) equilibrated with 50 mM formic acid, pH 3.7.
  • KFN 1651 was purified from yeast culture medium. The concentration of KFN 1651 was determined from the absorbance at 214 nm using BPTI as a standard. Porcine trypsin and human recombinant factor Vila was obtained from Novo Nordisk A/S (Bagsvaerd, Denmark), bovine chymotrypsin (TLCK treated) was obtained from Sigma Chemical Co. (St. Louis, MO, USA). Human truncated recombinant tissue factor was obtained from Corvas (San Diego, CA, USA).
  • Human neutrophil cathepsin G was purified from extracts of PMNs according to the method described by Baugh and Travis (Biochemistry 15 (1976) 836-843).
  • Peptidyl nitroanilide substrates, S2251, S2586, S2288 were from Kabi (Stockholm, Sweden).
  • S7388 was from Sigma Chemical Co. (St. Louis, MO, USA) and FXa-1 was from NycoMed (Oslo, Norway).
  • Serine proteinases were incubated with various concentrations of KFN 1651 for 30 min. Substrate was then added and residual proteinase activity was measured at 405 nm. The results are shown in Table 2.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Variant du domaine I des inhibiteurs de voie de Thromboplastine Tissulaire, inhibiteur de la protéase humaine de type Kumitz; le variant comprend la séquence d'acides aminés: X1 Cys Ala Phe Lys Ala Asp X?2 Gly X3 Cys X4 X5 X6 X7 X8 X¿9 Phe Phe Phe Asn Ile Phe Thr Arg Gln Cys Glu Glu Phe X10 Tyr Gly Gly Cys X?11 X12 X13¿ Gln Asn Arg Phe X14 Ser Leu Glu Glu Cys X15 X16 Met Cys Thr Arg X17 (SEQ ID No. 1) dans laquelle X1 représente H ou 1 à 7 résidus d'acide aminé survenant naturellement à l'exception de Cys, X2 à X16 représentent chacun indépendamment un résidu d'acide aminé survenant naturellement, et X17 représente OH ou 1 à 5 résidus d'acide aminé survenant naturellement à l'exception de Cys, à condition qu'au moins un des résidus d'acide aminé X1 à X17 soit différent du résidu d'acide aminé correspondant de la séquence naturelle.
PCT/DK1993/000005 1992-01-07 1993-01-07 Variant inhibiteur de la protease humaine de type kunitz WO1993014122A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP5511993A JPH07504891A (ja) 1992-01-07 1993-01-07 ヒトクニッツ型プロテアーゼインヒビターの変異体
AU33460/93A AU675926B2 (en) 1992-01-07 1993-01-07 A human kunitz-type protease inhibitor variant
EP93902106A EP0621872A1 (fr) 1992-01-07 1993-01-07 Variant inhibiteur de la protease humaine de type kunitz
NO942549A NO942549L (no) 1992-01-07 1994-07-06 Humanproteaseinhibitorvariant av Kunitz-type
FI943234A FI943234A0 (fi) 1992-01-07 1994-07-06 Ihmisen Kunitz-tyyppisen proteaasiestäjän muunnos

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DK9200002 1992-01-07
DKPCT/DK92/00002 1992-01-07
DKPCT/DK92/00340 1992-11-16
DK9200340 1992-11-16

Publications (1)

Publication Number Publication Date
WO1993014122A1 true WO1993014122A1 (fr) 1993-07-22

Family

ID=26068350

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK1993/000005 WO1993014122A1 (fr) 1992-01-07 1993-01-07 Variant inhibiteur de la protease humaine de type kunitz

Country Status (13)

Country Link
EP (1) EP0621872A1 (fr)
JP (1) JPH07504891A (fr)
AU (1) AU675926B2 (fr)
CA (1) CA2127246A1 (fr)
CZ (1) CZ164494A3 (fr)
FI (1) FI943234A0 (fr)
HU (1) HUT70293A (fr)
IL (1) IL104324A0 (fr)
NO (1) NO942549L (fr)
NZ (1) NZ246570A (fr)
RU (1) RU94036773A (fr)
WO (1) WO1993014122A1 (fr)
ZA (1) ZA9396B (fr)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995012674A1 (fr) * 1993-11-05 1995-05-11 Zymogenetics, Inc. Proteases inhibitrices humaines de type kunitz
WO1995018830A2 (fr) * 1994-01-11 1995-07-13 Protein Engineering Corporation Inhibiteurs de la plasmine humaine derives des domaines de kunitz
WO1995021601A2 (fr) * 1994-01-11 1995-08-17 Protein Engineering Corporation Proteines de 'domaine de kunitz' a activite antikallikreine, et leurs analogues
WO1996004378A2 (fr) * 1994-08-05 1996-02-15 Chiron Corporation Proteines chimeriques et muteines des inhibiteurs des voies du facteur tissulaire de la coagulation tfpi et tfpi-2
WO1996039519A1 (fr) * 1995-06-05 1996-12-12 Genentech, Inc. Inhibiteurs de kallicreine plasmique de type kunitz
WO1996040224A1 (fr) * 1995-06-07 1996-12-19 Chiron Corporation Regulation de la synthese et de la liberation de la cytokine
US5786328A (en) * 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
US5795954A (en) * 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
WO2000011034A1 (fr) * 1998-08-25 2000-03-02 Knut Kleesiek Mutant de l'inhibiteur de la voie de la thromboplastine tissulaire, sa sequence d'adn et son utilisation
US6103500A (en) * 1994-08-05 2000-08-15 Chiron Corporation Production of tissue factor pathway inhibitor
US6242414B1 (en) 1995-06-07 2001-06-05 Chiron Corporation Regulation of cytokine synthesis and release
WO2001094539A2 (fr) * 2000-05-26 2001-12-13 Shanghai Biowindow Gene Development Inc. Nouveau polypeptide, facteur humain d'inhibition 11 de type kazal, et polynucleotide codant ce polypeptide
EP1484339A3 (fr) * 1994-01-11 2005-03-02 Dyax Corporation Protéines de "Domaine de Kunitz" a actvité antikallikreine et acides nucléiques les codant
EP1542710A1 (fr) * 2002-08-28 2005-06-22 Dyax Corp. Procedes de conservation d'organes et de tissus
US6989369B2 (en) 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
US7064107B2 (en) 2002-06-07 2006-06-20 Dyax Corp. Prevention and reduction of blood loss
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
US7550427B2 (en) 2003-08-29 2009-06-23 Dyax Corp. Poly-pegylated protease inhibitors
US8450275B2 (en) 2010-03-19 2013-05-28 Baxter International Inc. TFPI inhibitors and methods of use
US8466108B2 (en) 2008-12-19 2013-06-18 Baxter International Inc. TFPI inhibitors and methods of use
US8637454B2 (en) 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
US8816055B2 (en) 2011-01-06 2014-08-26 Dyax Corp. Plasma kallikrein binding proteins
US8822653B2 (en) 2010-01-06 2014-09-02 Dyax Corp. Plasma kallikrein binding proteins
US8962563B2 (en) 2009-12-21 2015-02-24 Baxter International, Inc. TFPI inhibitors and methods of use
US11286307B2 (en) 2015-12-11 2022-03-29 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK408089D0 (da) * 1989-08-18 1989-08-18 Novo Nordisk As Proteiner

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Nature, Volume 338, No. --, April 1989, THOMAS J. GIRARD et al., "Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor", page 518 - page 520. *

Cited By (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728674A (en) * 1993-11-05 1998-03-17 Zymogenetics, Inc. Inhibition of blood coagulation by human-kunitz-type inhibitors
US7541449B2 (en) 1993-11-05 2009-06-02 Stc.Unm Human kunitz-type inhibitors and methods relating thereto
WO1995012674A1 (fr) * 1993-11-05 1995-05-11 Zymogenetics, Inc. Proteases inhibitrices humaines de type kunitz
US6656746B2 (en) 1993-11-05 2003-12-02 Zymogenetics, Inc. Antibodies to human kunitz-type inhibitor
US5914315A (en) * 1993-11-05 1999-06-22 Zymogenetics, Inc. Human Kunitz-type inhibitors and compositions thereof
EP2055716A1 (fr) * 1994-01-11 2009-05-06 Dyax Corporation Protéines de domaine de Kunitz à inhibition de kallicréine et acides nucléiques le codant
WO1995018830A2 (fr) * 1994-01-11 1995-07-13 Protein Engineering Corporation Inhibiteurs de la plasmine humaine derives des domaines de kunitz
WO1995018830A3 (fr) * 1994-01-11 1995-08-10 Protein Eng Corp Inhibiteurs de la plasmine humaine derives des domaines de kunitz
JP2013249302A (ja) * 1994-01-11 2013-12-12 Dyax Corp クニッツドメインから誘導されたヒトプラスミンの阻害剤
US7628983B2 (en) 1994-01-11 2009-12-08 Dyax Corp. Kallikrein-binding “Kunitz domain” proteins and analogues thereof
US7919462B2 (en) 1994-01-11 2011-04-05 Dyax Corp. Inhibitors of human plasmin derived from the Kunitz domains
JP2012111779A (ja) * 1994-01-11 2012-06-14 Dyax Corp クニッツドメインから誘導されたヒトプラスミンの阻害剤
EP2330127A3 (fr) * 1994-01-11 2012-07-11 Dyax Corporation Protéines de domaine de Kunitz à inhibition de kallicréine et acides nucléiques le codant
US8283321B2 (en) 1994-01-11 2012-10-09 Dyax Corp. Kallikrein-binding “Kunitz domain” proteins and analogues thereof
US6953674B2 (en) 1994-01-11 2005-10-11 Dyax Corp. Inhibitors of human plasmin derived from the kunitz domains
US5795865A (en) * 1994-01-11 1998-08-18 Dyax Corp. Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof
JP2009183281A (ja) * 1994-01-11 2009-08-20 Dyax Corp クニッツドメインから誘導されたヒトプラスミンの阻害剤
US8431359B2 (en) 1994-01-11 2013-04-30 Dyax Corp. Nucleic acids encoding polypeptide inhibitors of human plasmin derived from the Kunitz domains
EP1484339A3 (fr) * 1994-01-11 2005-03-02 Dyax Corporation Protéines de "Domaine de Kunitz" a actvité antikallikreine et acides nucléiques les codant
EP1489097A1 (fr) * 1994-01-11 2004-12-22 Dyax Corporation Inhibiteurs de la plasmine humaine dérivés des domaines de Kunitz
WO1995021601A3 (fr) * 1994-01-11 1995-09-21 Protein Eng Corp Proteines de 'domaine de kunitz' a activite antikallikreine, et leurs analogues
WO1995021601A2 (fr) * 1994-01-11 1995-08-17 Protein Engineering Corporation Proteines de 'domaine de kunitz' a activite antikallikreine, et leurs analogues
US5994125A (en) * 1994-01-11 1999-11-30 Dyax Corp. Kallikrein-inhibiting "Kunitz Domain" proteins and analogues thereof
US6010880A (en) * 1994-01-11 2000-01-04 Dyax Corp. Inhibitors of human plasmin derived from the kunitz domains
US6423498B1 (en) 1994-01-11 2002-07-23 Dyax Corp. Variegated Kunitz domain peptide library and uses thereof
US6071723A (en) * 1994-01-11 2000-06-06 Dyax Corp. Inhibitors of human plasmin derived from the Kunitz domains
US8663629B2 (en) 1994-01-11 2014-03-04 Dyax Corp. Kallikrein-binding “kunitz domain” proteins and analogues thereof
US6103499A (en) * 1994-01-11 2000-08-15 Dyax Corp. Inhibitors of human plasmin derived from the Kunitz domains
US5795954A (en) * 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
US5880256A (en) * 1994-03-04 1999-03-09 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
US5834244A (en) * 1994-03-04 1998-11-10 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
US5863893A (en) * 1994-03-04 1999-01-26 Genentech, Inc. Factor VIIa inhibitors from kunitz domain proteins
US5589359A (en) * 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
WO1996004378A2 (fr) * 1994-08-05 1996-02-15 Chiron Corporation Proteines chimeriques et muteines des inhibiteurs des voies du facteur tissulaire de la coagulation tfpi et tfpi-2
US5563123A (en) * 1994-08-05 1996-10-08 Chiron Corporation Chimeric proteins
WO1996004378A3 (fr) * 1994-08-05 1996-03-14 Chiron Corp Proteines chimeriques et muteines des inhibiteurs des voies du facteur tissulaire de la coagulation tfpi et tfpi-2
US6103500A (en) * 1994-08-05 2000-08-15 Chiron Corporation Production of tissue factor pathway inhibitor
US5696088A (en) * 1994-08-05 1997-12-09 Chiron Corporation Chimeric proteins
US6783960B2 (en) 1994-08-05 2004-08-31 Chiron Corporation Chimeric proteins
US5780265A (en) * 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
US5786328A (en) * 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
WO1996039519A1 (fr) * 1995-06-05 1996-12-12 Genentech, Inc. Inhibiteurs de kallicreine plasmique de type kunitz
US6242414B1 (en) 1995-06-07 2001-06-05 Chiron Corporation Regulation of cytokine synthesis and release
WO1996040224A1 (fr) * 1995-06-07 1996-12-19 Chiron Corporation Regulation de la synthese et de la liberation de la cytokine
AU708394B2 (en) * 1995-06-07 1999-08-05 Novartis Vaccines And Diagnostics, Inc. Regulation of cytokine synthesis and release
WO2000011034A1 (fr) * 1998-08-25 2000-03-02 Knut Kleesiek Mutant de l'inhibiteur de la voie de la thromboplastine tissulaire, sa sequence d'adn et son utilisation
WO2001094539A2 (fr) * 2000-05-26 2001-12-13 Shanghai Biowindow Gene Development Inc. Nouveau polypeptide, facteur humain d'inhibition 11 de type kazal, et polynucleotide codant ce polypeptide
WO2001094539A3 (fr) * 2000-05-26 2002-03-14 Shanghai Biowindow Gene Dev Nouveau polypeptide, facteur humain d'inhibition 11 de type kazal, et polynucleotide codant ce polypeptide
US7811991B2 (en) 2002-06-07 2010-10-12 Dyax Corp. Prevention and reduction of blood loss
US8710007B2 (en) 2002-06-07 2014-04-29 Dyax Corp. Prevention and reduction of blood loss
US10245307B2 (en) 2002-06-07 2019-04-02 Dyax Corp. Prevention and reduction of blood loss
US7704949B2 (en) 2002-06-07 2010-04-27 Dyax Corp. Kallikrein-inhibitor therapies
US11344610B2 (en) 2002-06-07 2022-05-31 Takeda Pharmaceutical Company Limited Prevention and reduction of blood loss
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
US7851442B2 (en) 2002-06-07 2010-12-14 Dyax Corp. Prevention and reduction of blood loss
US9114144B2 (en) 2002-06-07 2015-08-25 Dyax Corp. Kallikrein-inhibitor therapies
US8034775B2 (en) 2002-06-07 2011-10-11 Dyax Corp. Kallikrein-inhibitor therapies
US8124586B2 (en) 2002-06-07 2012-02-28 Dyax Corp. Prevention and reduction of blood loss
US9480733B2 (en) 2002-06-07 2016-11-01 Dyax Corp. Prevention and reduction of blood loss
US7064107B2 (en) 2002-06-07 2006-06-20 Dyax Corp. Prevention and reduction of blood loss
US7718617B2 (en) 2002-08-28 2010-05-18 Dyax Corp. Methods for preserving organs and tissues
EP2386310A3 (fr) * 2002-08-28 2012-06-13 Dyax Corp. Procédés de conservation d'organes et de tissus
EP1542710A1 (fr) * 2002-08-28 2005-06-22 Dyax Corp. Procedes de conservation d'organes et de tissus
EP1542710A4 (fr) * 2002-08-28 2007-11-28 Dyax Corp Procedes de conservation d'organes et de tissus
US7166576B2 (en) 2002-08-28 2007-01-23 Dyax Corp. Methods for preserving organs and tissues
AU2003243413B2 (en) * 2002-08-28 2009-07-09 Takeda Pharmaceutical Company Limited Methods for preserving organs and tissues
US6989369B2 (en) 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
US7550427B2 (en) 2003-08-29 2009-06-23 Dyax Corp. Poly-pegylated protease inhibitors
US8188045B2 (en) 2004-09-27 2012-05-29 Dyax Corp. Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US9757437B2 (en) 2004-09-27 2017-09-12 Dyax Corp. Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US8716225B2 (en) 2004-09-27 2014-05-06 Dyax Corp. Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
US9873720B2 (en) 2008-12-19 2018-01-23 Baxalta GmbH TFPI inhibitors and methods of use
US8466108B2 (en) 2008-12-19 2013-06-18 Baxter International Inc. TFPI inhibitors and methods of use
US11001613B2 (en) 2008-12-19 2021-05-11 Takeda Pharmaceutical Company Limited TFPI inhibitors and methods of use
US9777051B2 (en) 2008-12-19 2017-10-03 Baxalta GmbH TFPI inhibitors and methods of use
US8637454B2 (en) 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
US8962563B2 (en) 2009-12-21 2015-02-24 Baxter International, Inc. TFPI inhibitors and methods of use
US8822653B2 (en) 2010-01-06 2014-09-02 Dyax Corp. Plasma kallikrein binding proteins
US11505620B2 (en) 2010-01-06 2022-11-22 Takeda Pharmaceutical Company Limited Methods of detecting plasma kallikrein
US10336832B2 (en) 2010-01-06 2019-07-02 Dyax Corp. Methods of inhibiting plasma kallikrein in edema patient
US10201586B2 (en) 2010-03-19 2019-02-12 Baxalta GmbH TFPI inhibitors and methods of use
US9018167B2 (en) 2010-03-19 2015-04-28 Baxter International Inc. TFPI inhibitors and methods of use
US9556230B2 (en) 2010-03-19 2017-01-31 Baxalta GmbH TFPI inhibitors and methods of use
US8450275B2 (en) 2010-03-19 2013-05-28 Baxter International Inc. TFPI inhibitors and methods of use
US11793855B2 (en) 2010-03-19 2023-10-24 Takeda Pharmaceutical Company Limited TFPI inhibitors and methods of use
US10370453B2 (en) 2011-01-06 2019-08-06 Dyax Corp. Plasma kallikrein binding proteins
US8816055B2 (en) 2011-01-06 2014-08-26 Dyax Corp. Plasma kallikrein binding proteins
US11401346B2 (en) 2011-01-06 2022-08-02 Takeda Pharmaceutical Company Limited Nucleic acids encoding plasma kallikrein binding proteins
US9266964B2 (en) 2011-01-06 2016-02-23 Dyax Corp. Method of treating hereditary angioedema using plasma kallikrein binding antibodies
US10800816B2 (en) 2012-03-21 2020-10-13 Baxalta GmbH TFPI inhibitors and methods of use
US11286307B2 (en) 2015-12-11 2022-03-29 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack

Also Published As

Publication number Publication date
ZA9396B (en) 1993-08-10
RU94036773A (ru) 1996-09-27
EP0621872A1 (fr) 1994-11-02
AU675926B2 (en) 1997-02-27
NO942549D0 (no) 1994-07-06
NZ246570A (en) 1996-09-25
AU3346093A (en) 1993-08-03
JPH07504891A (ja) 1995-06-01
FI943234L (fi) 1994-07-06
HUT70293A (en) 1995-09-28
HU9401990D0 (en) 1994-09-28
IL104324A0 (en) 1993-05-13
CZ164494A3 (en) 1994-12-15
NO942549L (no) 1994-09-07
FI943234A0 (fi) 1994-07-06
CA2127246A1 (fr) 1993-07-22

Similar Documents

Publication Publication Date Title
AU676145B2 (en) A human kunitz-type protease inhibitor variant
AU675926B2 (en) A human kunitz-type protease inhibitor variant
AU675925B2 (en) A human kunitz-type protease inhibitor variant
AU671611B2 (en) Human kunitz-type protease inhibitor variants
EP0621873B1 (fr) Nouvel inhibiteur de protease humaine de type kunitz et ses variants

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CZ FI HU JP KR NO NZ PL RU SK US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1993902106

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 246570

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2127246

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 943234

Country of ref document: FI

WWE Wipo information: entry into national phase

Ref document number: PV1994-1644

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1993902106

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1994-1644

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1993902106

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV1994-1644

Country of ref document: CZ

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载